.
Vendredi 10 avril à 14h30 / Friday 10 April at 2.30 p.m
Amphi 5 (5e bleu)
Introduction :
Ming-Li Chou
Invitée par l’Equipe 2 / Invited by Team 2
Innovative platelet lysate therapies in neurodegenerative diseases
Human platelets are rich in bioactive molecules, including growth factors, antioxidative and anti-inflammatory agents, and extracellular vesicles, which collectively promote tissue repair and regeneration. Heat-treated human platelet pellet lysates (HPPL) have demonstrated neuroprotective and anti-inflammatory effects in preclinical models of CNS injury, particularly when administrated intranasally. This innovative approach has spurred the development of novel therapies for neurodegenerative diseases such as Parkinson’s and Amyotrophic Lateral Sclerosis (ALS), leding to the establishment of InVenis Biotherapies, and a major €8.4 million research project funded by the French government’s France 2030 Plan.
Our research focuses on elucidating the mechanisms underlying the neuroimmunomodulatory effects of platelet lysate, with a specific emphasis on its impact on mitochondrial function, remyelination, and neutrophil-platelet interactions during intranasal delivery in inflammatory contexts. By dissecting these pathways, we aim to enhance translational evaluation and optimize therapeutic outcomes.